Sex hormone replacement therapy for individuals with Turner syndrome.


Journal

American journal of medical genetics. Part C, Seminars in medical genetics
ISSN: 1552-4876
Titre abrégé: Am J Med Genet C Semin Med Genet
Pays: United States
ID NLM: 101235745

Informations de publication

Date de publication:
03 2019
Historique:
received: 22 10 2018
accepted: 05 12 2018
pubmed: 28 2 2019
medline: 31 3 2020
entrez: 28 2 2019
Statut: ppublish

Résumé

Turner syndrome is a relatively common genetic condition resulting from absence of all or part of the second sex chromosome. Individuals with Turner syndrome commonly exhibit cardiovascular, endocrine, renal, reproductive, and/or psychosocial abnormalities, among other conditions. Most girls with Turner syndrome have hypergonadotropic hypogonadism and therefore need sex steroid hormonal replacement therapy. The optimal estrogen replacement treatment regimen to induce pubertal development is still being determined. The goals of the estrogen replacement are to mimic the normal physical and social development for timing and progression of puberty. Treatment should begin at 11-12 years of age, with dose increases every 6 months over a 2-3 year period. Initiation with low doses of estrogen is crucial to preserve growth potential. On the other hand, delaying estrogen replacement may be deleterious to bone and uterine health.

Identifiants

pubmed: 30809949
doi: 10.1002/ajmg.c.31685
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

13-17

Subventions

Organisme : NCATS NIH HHS
ID : UL1 TR000371
Pays : United States

Informations de copyright

© 2019 Wiley Periodicals, Inc.

Auteurs

Philippe Backeljauw (P)

Division of Pediatric Endocrinology, The Cincinnati Center for Pediatric and Adult Turner Syndrome Care, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, Ohio.

Karen Klein (K)

Division of Pediatric Endocrinology, Rady Children's Hospital and University of California, San Diego, California.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH